Medhija LLC Launches Prolistem a Supportive Treatment Supplement for Men With Non Obstructive Azoospermia
Aug 1, 2023
Medhija LLC is a premier American med-tech company and creator of an innovative treatment for non-obstructive azoospermia. The company offers multiple series of products designed to help men with zero sperm count.
United States - August 1, 2023 /MarketersMEDIA/ —
"Dr. Abuelhija presents Prolistem at the European Society of Human Reproductive and Embryonic Medicine (ESHRE 2023)."
Azoospermia is “a condition in which there’s no measurable sperm in a man’s ejaculate” and is one of the leading causes of male infertility. According to data sourced from clevelandclinic.org, it is estimated that approximately 1% of all men and 10-15% of infertile men worldwide struggle with this condition.
Non-obstructive azoospermia refers to zero sperm count and is, fortunately, treatable. While incurable, this condition can be mended by extremely expensive, experimental, and somewhat risky medical procedures. Medhija LLC one of the leading American med-tech companies offers Prolistem, a better alternative – a science-backed treatment designed for men with non obstructive azoospermia.
Prolistem is helmed by Dr. Abuelhija, an internationally renowned scientist who is committed to pushing the boundaries of medical science and creating actionable solutions that modern medicine has not been able to.
Knowing that thousands of men across the globe have low or zero sperm count, Dr. Abuelhija and his team of passionate medical experts and scientists began working on a revolutionary treatment that could significantly increase the odds of successful sperm extraction surgeries.
“Men with non-obstructive azoospermia are often told their condition is incurable and that they will never become a parent. This is devastating for so many men who desperately want to be a father. Prolistem is the next generation of treatment for men with non-obstructive azoospermia. Formulated by experts and patented, our six-month course of supplements could raise your sperm count and improve your chances of a successful sperm-extraction surgery,” said Prolistem’s spokesperson.
Prolistem is a product of years of research, clinical trials, and innovation. Unlike contemporary alternatives, Prolistem uses not one but a variety of cutting-edge materials to craft its azoospermia supplement solutions, with the most prominent being glycyrrhizic acid.
According to Dr. Abuelhija, Prolistem has already shown remarkable success across the board:
“Our innovative course has yielded impressive success rates, with 48% of patients achieving successful outcomes. Among them, 23% of patients had sperm detected in their semen while 25% of patients had successful surgical sperm extractions following the completion of Prolistem course,” the firm’s spokesperson continued.
Prolistem’s formula features glycyrrhizic acid sourced from a special type of licorice to suppress 17-beta enzymes, and consequentially suppress testosterone levels. This way, Prolistem promotes better spermatogenesis. The primary purpose of using Prolistem is to restore germ cell development and ultimately restore the patient’s fertility.
Prolistem has been widely hailed as the only fertility supplement that tackles non-obstructive azoospermia. While the majority of contemporary alternatives target a variety of other fertility-related issues, Prolistem’s laser focus on suppressing testosterone and boosting spermatogenesis is showing incomparably better results.
More information about Prolistem is available on the company’s official website.
Contact Info:
Name: Prolistem Team
Email: Send Email
Organization: MedHija LLC
Phone: 8452336550
Website: http://www.prolistem.com/
Release ID: 89103608
Should any problems, inaccuracies, or doubts arise from the content contained within this press release, we kindly request that you inform us immediately by contacting [email protected]. Our dedicated team will promptly address your concerns within 8 hours, taking necessary steps to rectify identified issues or assist with the removal process. Providing accurate and dependable information is at the core of our commitment to our readers.
More News
Anthropic Pursues IPO Despite Its A.I. Safety Warnings
The company is expected to reach $100 billion in annualized revenue this year, even as chief executive Dario Amodei calls for slowing down development of some advanced A.I. models.
Native American Tribe Teams Up With Kalshi on New Prediction Market
The Tunica-Biloxi of Louisiana plan to release a platform that uses infrastructure by Kalshi, the industry leader. Other tribes have taken aim at the company.
Trump Promotes Program to Reduce Medicaid Drug Prices
Ahead of the midterm elections, the president said that all states had opted in to an effort to align Medicaid’s prices for medicines with those in other wealthy countries.
Who Is Howard Buffett, the New Berkshire Hathaway Chairman?
Mr. Buffett, 71, is succeeding his father, Warren, but will not be running the company’s day-to-day operations.
Uber to Pay $40 Million to Parents of Woman Fatally Hit by Car
Emily Normandin-Parker, 23, was struck and killed on a California freeway after an Uber driver ordered her and a friend out of his car in August 2023.
S.E.C. Seeks to End Shareholder Proposals Process Commonly Used by Activists
Activists have often used the rule to push for changes in companies’ governance and environmental and social policies.
'We simply don't know' - JP Morgan struggling to forecast oil prices due to Trump's war with Iran
The bank said it "assumed" there would be economic red lines, like oil at $100 a barrel, that the US would be unwilling the cross.
Warren Buffett steps down after six decades at Berkshire - 'Father Time always wins'
Since taking control in 1965, Buffett grew a struggling textile mill into a global conglomerate.
Ryanair boss Michael O'Leary apologises over 'high-fare rapists' remarks
O'Leary described his choice of language as "careless" and said "it won't happen again".
What Set Off the Rise in Interest Rates? Mainly, the Iran War.
The Federal Reserve is trying to catch up with the leap in bond rates as the Middle East conflict unnerves world markets.
The A.I. Industry’s New Worry: ‘Liability Exposure’
The prospect of artificial intelligence tools being used to do significant harm presents the companies and their leaders with a legal challenge.
Disney Hires Its First CTO Amid Industry Push to Embrace A.I.
Karandeep Anand, an expert in building artificial intelligence and consumer technology products, will become Disney’s first chief technology officer.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.